enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves new type of schizophrenia drug - AOL

   www.aol.com/news/fda-approves-type-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

3. Brilaroxazine - Wikipedia

   en.wikipedia.org/wiki/Brilaroxazine

   RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...

4. FDA Approves the First New Schizophrenia Drug in Decades - AOL

   www.aol.com/fda-approves-first-schizophrenia...

   N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...

5. Management of schizophrenia - Wikipedia

   en.wikipedia.org/wiki/Management_of_schizophrenia

   The management of schizophrenia usually involves many aspects including psychological, pharmacological, social, educational, and employment-related interventions directed to recovery, and reducing the impact of schizophrenia on quality of life, social functioning, and longevity.

6. Soteria (psychiatric treatment) - Wikipedia

   en.wikipedia.org/wiki/Soteria_(psychiatric...

   Based on a recovery model, the common elements of the Soteria approach include the use of primarily nonmedical staff, who do not prescribe or administer antipsychotic medication to patients, and the preservation of residents' personal power, social networks, and communal responsibilities. [2]

7. Schizophrenia In America - The Huffington Post

   highline.huffingtonpost.com/articles/en/stop-the...

   And while antipsychotics can help schizophrenia’s “positive” symptoms, such as hallucinations, they have a minimal impact on the “negative” symptoms, which are arguably more devastating. People who have schizophrenia can lose the ability to focus, to sustain effort, to carry on a conversation or to maintain eye contact.